Add BrightSurf on Google Email

Johns Hopkins Medicine


FDA approved new immunotherapy regimen for patients with melanoma based on Johns Hopkins Research

The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.

SourceJohns Hopkins Medicine·JournalNew England Journal of Medicine·DateMar 23, 2022

Making the invisible visible: A clearer ‘picture’ of blood vessels in health and disease thanks to new imaging approach

Researchers developed a new imaging approach called VascuViz to visualize blood vessels at different spatial scales. The method enables detailed mathematical models and complementary images to clarify the role of blood flow in health and disease, advancing our understanding of tissues throughout the body.

SourceJohns Hopkins Medicine·JournalNature Methods·DateFeb 28, 2022

Patient safety program reduces unnecessary antibiotic use in long-term care facilities

A study published in JAMA Network Open shows that a comprehensive system to improve antibiotic stewardship in long-term care facilities significantly reduces the use of antibiotics, leading to better patient outcomes and reduced drug-resistant bacterial strains. The program empowered clinicians to make informed decisions about prescrib...

SourceJohns Hopkins Medicine·JournalJAMA Network Open·DateFeb 28, 2022

SARS-CoV-2 protein targeted by immune cells also triggers response in bat Coronaviruses

Researchers at Johns Hopkins Medicine discovered a peptide on the SARS-CoV-2 spike protein that triggers an immune response in humans and is also recognized by cells of the immune system, suggesting potential for protection against future zoonotic outbreaks. The study supports the development of multivalent vaccines against a broad spe...

SourceJohns Hopkins Medicine·JournalJournal of Clinical Investigation·DateFeb 16, 2022

Psilocybin treatment for major depression effective for up to a year for most patients, study shows

A study by Johns Hopkins Medicine researchers found that psilocybin-assisted therapy can lead to significant and durable improvements in depression, with effects lasting at least a year for most patients. The treatment was shown to produce large decreases in depression severity and stable rates of response throughout the follow-up period.

SourceJohns Hopkins Medicine·JournalJournal of Psychopharmacology·DateFeb 15, 2022

Special testing of kidney tissue from deceased COVID-19 donor documents safe transplantation of the organ, Johns Hopkins researchers report

Researchers at Johns Hopkins Medicine have successfully transplanted a kidney from a COVID-19 donor, demonstrating that healthy kidneys from such donors can be safely transplanted. The recipient has shown no signs or symptoms of the virus and has excellent kidney function since the transplant.

SourceJohns Hopkins Medicine·JournalAmerican Journal of Transplantation·DateJan 31, 2022

Young sexual minority men and transgender women are at higher risk of transactional sex

A recent survey by Johns Hopkins Medicine researchers found that about 22% of young sexual minority males and transgender females engage in transactional sex. The practice is associated with HIV exposure, substance use disorder, and unstable housing. Researchers plan to develop interventions to address economic and social vulnerabilities.

SourceJohns Hopkins Medicine·JournalJournal of Adolescent Health·DateJan 25, 2022

Large field hospital study shows rapid Covid-19 test compares solidly with PCR detection

A large field hospital study shows that a rapid Covid-19 test is as accurate as PCR detection, with high sensitivity rates for both symptomatic and asymptomatic patients. The rapid antigen test's ease of use, time savings, and cost effectiveness make it an ideal solution to reduce testing disparities in medically underserved communities.

SourceJohns Hopkins Medicine·JournalMicrobiology Spectrum·DateDec 7, 2021

Mouse study suggests manipulation of certain nerve cells can help regenerate lost heart muscle

Researchers at Johns Hopkins Medicine have discovered that manipulating certain nerve cells may trigger the formation of new heart muscle cells, restoring heart function after heart attacks. The study found that removing specific genes associated with circadian rhythms increased neonatal heart size and cardiomyocyte numbers by up to 10%.

SourceJohns Hopkins Medicine·JournalScience Advances·DateDec 2, 2021

Simultaneous repair of heart valves may benefit some adults

A two-year follow-up of participants found that those who had both their mitral valve and tricuspid valve repaired at the same time experienced better outcomes, including less progression to moderate or severe leakage. This study provides high-level evidence for surgeons on how to perform tricuspid valve repair in these patients.

SourceJohns Hopkins Medicine·JournalNew England Journal of Medicine·DateNov 16, 2021

Study shows immune cells against COVID-19 stay high in number six months after vaccination

Researchers found that CD4+ T lymphocytes — immune system cells — produced by people who received COVID-19 vaccines persisted at high levels six months after vaccination, with a significant response against the delta variant. The study also showed that vaccine-elicited fighters recognize and help attack coronavirus delta variant.

SourceJohns Hopkins Medicine·JournalClinical Infectious Diseases·DateNov 16, 2021

Mouse cell studies show that correcting DNA disorganization could aid diagnosis and treatment of rare inherited diseases

A study with lab-grown mouse cells reveals that lamin C plays a key role in maintaining the structural network under the cell's nucleus, ensuring proper DNA organization. This finding has significant implications for diagnosing and treating genetic disorders linked to DNA disorganization, such as progeria and muscular dystrophy.

SourceJohns Hopkins Medicine·JournalGenome Biology·DateNov 14, 2021

Immunotherapy-chemotherapy treatment coupled with in-depth genomic analyses leads to improved survival for patients with mesothelioma

Researchers at Johns Hopkins Kimmel Cancer Center found a new treatment option for inoperable pleural mesothelioma using immunotherapy agent durvalumab combined with platinum-based chemotherapy. Patients with epithelioid tumors experienced higher survival rates, including some who remained tumor-free after completing the trial.

SourceJohns Hopkins Medicine·JournalNature Medicine·DateNov 8, 2021

Hopkins Med newsletter 7

Researchers identified a pattern that links the accumulation of amyloid beta (Aβ) proteins with a reduction of serotonin, which may help predict who will develop late-life depression. The study found that individuals expressing this pattern had more severe depressive symptoms.

SourceJohns Hopkins Medicine·JournalTranslational Psychiatry·DateOct 7, 2021

Experimental drug development approach points to better targeted therapies for treatment-resistant leukemia

Researchers have identified a way to restore the effectiveness of drugs in clinical trials for treating AML by using human alpha(1)-acid glycoprotein (AGP) as a 'decoy' to bind and inhibit FLT3-mutated leukemia cells. The approach has potential for improving patient outcomes, particularly for patients with FLT3-mutated AML.

SourceJohns Hopkins Medicine·JournalBlood Cancer Discovery·DateSep 27, 2021